For research use only. Not for therapeutic Use.
Corrector C4 (Cat No.: I011829) is an investigational compound being studied for its potential to treat cystic fibrosis (CF), particularly by addressing the defective CFTR (cystic fibrosis transmembrane conductance regulator) protein. It functions as a CFTR corrector, helping to improve the folding and trafficking of the mutated protein to the cell surface, where it can restore normal chloride ion transport. Preclinical studies suggest that Corrector C4 may enhance the efficacy of CFTR modulators, offering potential benefits for patients with specific CF mutations. Clinical trials are ongoing to assess its effectiveness.
| CAS Number | 421580-53-2 |
| Synonyms | Corrector C4; Corrector C-4; Corrector C 4; Corr-4a; Corr 4a; Corr4a;;N-(2-((5-chloro-2-methoxyphenyl)amino)-4/’-methyl-[4,5/’-bithiazol]-2/’-yl)benzamide |
| Molecular Formula | C21H17ClN4O2S2 |
| Purity | ≥95% |
| Solubility | Soluble in DMSO |
| Storage | Store at 0-8 °C |
| IUPAC Name | N-[5-[2-(5-chloro-2-methoxyanilino)-1,3-thiazol-4-yl]-4-methyl-1,3-thiazol-2-yl]benzamide |
| InChI | InChI=1S/C21H17ClN4O2S2/c1-12-18(30-21(23-12)26-19(27)13-6-4-3-5-7-13)16-11-29-20(25-16)24-15-10-14(22)8-9-17(15)28-2/h3-11H,1-2H3,(H,24,25)(H,23,26,27) |
| InChIKey | RDOBOPJBMQURAT-UHFFFAOYSA-N |
| SMILES | CC1=C(SC(=N1)NC(=O)C2=CC=CC=C2)C3=CSC(=N3)NC4=C(C=CC(=C4)Cl)OC |
| Reference | </br>1: Dekkers JF, Gogorza Gondra RA, Kruisselbrink E, Vonk AM, Janssens HM, de Winter-de Groot KM, van der Ent CK, Beekman JM. Optimal correction of distinct CFTR folding mutants in rectal cystic fibrosis organoids. Eur Respir J. 2016 Aug;48(2):451-8. doi: 10.1183/13993003.01192-2015. Epub 2016 Apr 21. PubMed PMID: 27103391.</br>2: van der Woerd WL, Wichers CG, Vestergaard AL, Andersen JP, Paulusma CC, Houwen RH, van de Graaf SF. Rescue of defective ATP8B1 trafficking by CFTR correctors as a therapeutic strategy for familial intrahepatic cholestasis. J Hepatol. 2016 Jun;64(6):1339-47. doi: 10.1016/j.jhep.2016.02.001. Epub 2016 Feb 12. PubMed PMID: 26879107.</br>3: Bali V, Lazrak A, Guroji P, Fu L, Matalon S, Bebok Z. A synonymous codon change alters the drug sensitivity of ΔF508 cystic fibrosis transmembrane conductance regulator. FASEB J. 2016 Jan;30(1):201-13. doi: 10.1096/fj.15-273714. Epub 2015 Sep 3. PubMed PMID: 26336913; PubMed Central PMCID: PMC4684529.</br>4: Lopes-Pacheco M, Boinot C, Sabirzhanova I, Morales MM, Guggino WB, Cebotaru L. Combination of Correctors Rescue ΔF508-CFTR by Reducing Its Association with Hsp40 and Hsp27. J Biol Chem. 2015 Oct 16;290(42):25636-45. doi: 10.1074/jbc.M115.671925. Epub 2015 Sep 2. PubMed PMID: 26336106; PubMed Central PMCID: PMC4646207.</br>5: Farinha CM, Sousa M, Canato S, Schmidt A, Uliyakina I, Amaral MD. Increased efficacy of VX-809 in different cellular systems results from an early stabilization effect of F508del-CFTR. Pharmacol Res Perspect. 2015 Aug;3(4):e00152. doi: 10.1002/prp2.152. Epub 2015 Jun 11. PubMed PMID: 26171232; PubMed Central PMCID: PMC4492728.</br>6: Rapino D, Sabirzhanova I, Lopes-Pacheco M, Grover R, Guggino WB, Cebotaru L. Rescue of NBD2 mutants N1303K and S1235R of CFTR by small-molecule correctors and transcomplementation. PLoS One. 2015 Mar 23;10(3):e0119796. doi: 10.1371/journal.pone.0119796. eCollection 2015. PubMed PMID: 25799511; PubMed Central PMCID: PMC4370480.</br>7: Holleran JP, Zeng J, Frizzell RA, Watkins SC. Regulated recycling of mutant CFTR is partially restored by pharmacological treatment. J Cell Sci. 2013 Jun 15;126(Pt 12):2692-703. doi: 10.1242/jcs.120196. Epub 2013 Apr 9. PubMed PMID: 23572510; PubMed Central PMCID: PMC3687701.</br>8: Yu GJ, Yoo CL, Yang B, Lodewyk MW, Meng L, El-Idreesy TT, Fettinger JC, Tantillo DJ, Verkman AS, Kurth MJ. Potent s-cis-locked bithiazole correctors of DeltaF508 cystic fibrosis transmembrane conductance regulator cellular processing for cystic fibrosis therapy. J Med Chem. 2008 Oct 9;51(19):6044-54. doi: 10.1021/jm800533c. Epub 2008 Sep 13. PubMed PMID: 18788728; PubMed Central PMCID: PMC3167067.</br></br> |
